Incidence and predictors of exceptional response (ExRes) in patients (pts) initiating first-line (1L) treatment for HER2-positive (HER2+) metastatic breast cancer (MBC).

Authors: Sarah L. Sammons, Jose Pablo Leone, Thibaut Sanglier, Jocelyn Sun, Peter Lambert, Raf Poppe, Estefania Monturus, Adam Knott, Eleonora Restuccia, Nancy U. Lin, Sara M. Tolaney

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e13021

Source: Full article

---

Abstract

e13021